Bristol-Myers Squibb has been given a boost by trial results which suggest its compound for hepatitis C, PEG-Interferon lambda, is …
MHRA approves Romvimza for tenosynovial giant cell tumour
Panthera opens clinical trial site at Keele University
Santen joins inaugural Global Summit for Eye Health as partner

